Results 31 to 40 of about 236,269 (292)

Liquid biopsies and minimal residual disease in myeloid malignancies

Frontiers in Oncology, 2023
Minimal residual disease (MRD) assessment through blood component sampling by liquid biopsies (LBs) is increasingly being investigated in myeloid malignancies.
Sabine Allam, Kristina Nasr, Farhan Khalid, Zunairah Shah, Mahammed Ziauddin Khan Suheb, Sana Mulla, Sindhu Vikash, Maroun Bou Zerdan, Faiz Anwer, Chakra P. Chaulagain   +9 more
doaj   +1 more source

Molecular Minimal Residual Disease in Acute Myeloid Leukemia [PDF]

, 2018
BACKGROUND Patients with acute myeloid leukemia (AML) often reach complete remission, but relapse rates remain high. Next-generation sequencing enables the detection of molecular minimal residual disease in virtually every patient, but its clinical ...
Kavelaars, François, Jongen-Lavrencic, Mojca, Erpelinck - Verschueren, Claudia, Zeilemaker, Annelieke, Peter J.M. Valk, van Marwijk Kooy, Marinus, Al Hinai, Adil, Manz, M. G., Pabst Müller, Thomas Niklaus, Thomas Pabst, Passweg, JR, Cloos, J., Biemond, Bart J, Rosa Meijer, Havelange, V, Erpelinck-Verschueren, Claudia A J, Passweg, J. R., Passweg, Jakob R, Kavelaars, François G, Jakob R. Passweg, Annelieke Zeilemaker, Hanekamp, Diana, Hanekamp, D., Pabst, Thomas, Jacqueline Cloos, Bart J. Biemond, Markus G. Manz, Meijer, R, François G. Kavelaars, Havelange, V., Cloos, Jacqueline, van Marwijk Kooy, M., Meijer, R., Sanders, Mathijs A, Schuurhuis, GJ, Grob, T., Violaine Havelange, Bob Löwenberg, Gradowska, Patrycja L, Marinus van Marwijk Kooy, Mojca Jongen-Lavrencic, Gert J. Ossenkoppele, Havelange, Violaine, Sanders, Mathijs, Sanders, M. A., Valk, Peter, Löwenberg, Bob; id_orcid, Graux, C., Zeilemaker, A., Mathijs A. Sanders, Pabst, T, Manz, Markus G, Biemond, B. J., Carlos Graux, Gradowska, P. L., Löwenberg, Bob, Erpelinck-Verschueren, C. A. J., Ossenkoppele, GJ, Lowenberg, B., Diana Hanekamp, Meijer, Rosa, Jongen - Lavrencic, Mojca, Jongen-Lavrencic, M., Biemond, BJ, Ossenkoppele, G. J., Valk, P. J. M., Cloos, J, Pabst, T., Claudia A.J. Erpelinck-Verschueren, Adil al Hinai, Grob, Tim, Schuurhuis, G. J., Al Hinai, A., Tim Grob, Graux, C, Graux, Carlos, Schuurhuis, Gerrit J, Kavelaars, F. G., Kooy, MV, Manz, MG, Valk, Peter J M, Gerrit J. Schuurhuis, Ossenkoppele, Gert J, Patrycja L. Gradowska, Hanekamp, D, Gradowska, Patrycja   +85 more
core   +1 more source

Transforming ovarian cancer care by targeting minimal residual disease [PDF]

, 2023
Frontline treatment and resultant cure rates in patients with advanced ovarian cancer have changed little over the past several decades. Here, we outline a multidisciplinary approach aimed at gaining novel therapeutic insights by focusing on the poorly ...
Moiso, Enrico, Wucherpfennig, Kai W, Konstantinopoulos, Panagiotis A, Hillman, R Tyler, Weigelt, Britta, Bardhan, Neelkanth M, Aghajanian, Carol, Knisely, Anne, Pisanic, Thomas, Shih, IeMing, Lu, Karen H, Lee, Sanghoon, Spranger, Stefani, Jazaeri, Amir A, D’Andrea, Alan D, Gaillard, Stephanie, Williams, Marc J, Matulonis, Ursula, Wang, Linghua, Burns, Kathleen H, Westin, Shannon N, Grisham, Rachel, Hammond, Paula, Lawson, Barrett C, Zamarin, Dmitriy, Shah, Sohrab   +25 more
core   +4 more sources

Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia [PDF]

, 2014
The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD).
van den Ancker, W. (Willemijn), Ham, S.M. (Marieke) van, van de Loosdrecht, Arjan A., van Luijn, M.M., Luijn, M.M. (Marvin) van, van den Ancker, Willemijn, van de Loosdrecht, A.A., Loosdrecht, A.A. (Arjan) van de, van Ham, S. Marieke, van Luijn, Marvin M.; id_orcid, van Ham, S.M., van den Ancker, W., van Luijn, Marvin M.   +12 more
core   +1 more source

Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia

Haematologica, 2010
Background The presence of minimal residual disease detected by polymerase chain reaction techniques prior to allogeneic hematopoietic stem cell transplantation has proven to be an independent prognostic factor for poor outcome in children with acute ...
Izaskun Elorza, Carlos Palacio, Jose Luis Dapena, Laura Gallur, José Sánchez de Toledo, Cristina Díaz de Heredia   +5 more
doaj   +1 more source

Metabolic memory underlying minimal residual disease in breast cancer

Molecular Systems Biology, 2021
Tumor relapse from treatment‐resistant cells (minimal residual disease, MRD) underlies most breast cancer‐related deaths. Yet, the molecular characteristics defining their malignancy have largely remained elusive.
Ksenija Radic Shechter, Eleni Kafkia, Katharina Zirngibl, Sylwia Gawrzak, Ashna Alladin, Daniel Machado, Christian Lüchtenborg, Daniel C Sévin, Britta Brügger, Kiran R Patil, Martin Jechlinger   +10 more
doaj   +1 more source

The Value of Minimal Residual Disease (and Diamonds) [PDF]

Biology of Blood and Marrow Transplantation, 2017
n ...
openaire   +3 more sources

Detection of minimal residual disease in acute lymphoblastic leukemia [PDF]

, 2010
Deep insight on Detection of minimal residual disease in acute lymphoblastic ...
D Campana, Campana, D
core   +1 more source

Cancer Special Issue: Early detection and minimal residual disease.

PLoS Medicine, 2021
Beryne Odeny discusses PLOS Medicine's Special Issue on early cancer detection and minimal residual disease.
Beryne Odeny
doaj   +1 more source

Monitoring of minimal residual disease in acute myeloid leukemia [PDF]

, 2004
Deep insight on Monitoring of minimal residual disease in acute myeloid ...
Schnittger, S, Kern, W, Schoch, C, Haferlach, T   +3 more
core   +1 more source